Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Amplia Therapeutics (ATX)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
EBR Systems (EBR)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Patrys (PAB)
PYC Therapeutics
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
June 21st, 2025
Private Company Preview: PLL Therapeutics' Novel Approach to Slow ALS (MND)
Read More
June 18th, 2025
Rhinomed to Become Acquired by Major Shareholder
Read More
June 17th, 2025
IPO Window Opening – Tetratherix
Read More
June 17th, 2025
Patrys – One Setback Too Many
Read More
June 3rd, 2025
Chimeric Therapeutics to Raise $6.6 Million with Early Encouraging Data Emerging
Read More
June 2nd, 2025
Cosette Threatens to Walk From $672 Million Mayne Takeover
Read More
June 1st, 2025
Avecho Finds Opportunity in CBD Australian Market
Read More
May 30th, 2025
Amplia Therapeutics Reaches Target Endpoint Early
Read More
May 14th, 2025
Chimeric Seeking Early Positive Data for Commercial Deal
Read More
May 14th, 2025
Blinklab Raises $7.7 Million
Read More
May 14th, 2025
Aroa Biosurgery March Quarter Receipts Up 12%
Read More
May 14th, 2025
Neuren Pharmaceuticals - DAYBUE Sales Up 11%
Read More
May 14th, 2025
Strong Launch for Botanix Pharmaceuticals' Sofdra
Read More
May 13th, 2025
Clinuvel Completes Recruitment in First Pivotal Vitiligo Study
Read More
May 13th, 2025
Dimerix Stuns Market with Major US Licensing Deal
Read More
May 12th, 2025
Increased Adoption of APAS and Profitable Business Ahead for Clever Culture Systems
Read More
April 29th, 2025
Anteris - Share Price Down as Company Plans for Pivotal Global study in 2025
Read More
April 28th, 2025
EBR Systems Gains FDA-Approval for Cardiac Resynchronisation
Read More
April 28th, 2025
Neuren Confirms Endpoints for Phase III Study in PMS
Read More
April 28th, 2025
Oversold Biotechs – Deserved or Not?
Read More
Pages
1
2
3
4
5
6
7
8
9
